Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Deloitte
Teva
AstraZeneca
Johnson and Johnson
US Department of Justice
Fuji
Dow
Colorcon
McKinsey

Generated: November 15, 2018

DrugPatentWatch Database Preview

Drugs in Development Information for Pembrolizumab

« Back to Dashboard

US Patents for Pembrolizumab

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Pembrolizumab ➤ Try a Free Trial Methods for the treatment of Kaposi's sarcoma or KSHV-induced lymphoma using immunomodulatory compounds, and uses of biomarkers Celgene Corporation (Summit, NJ) The United States of America, as Represented by the Secretary, Department of Health and Human Services (Washington, DC) ➤ Try a Free Trial
Pembrolizumab ➤ Try a Free Trial Antibody-drug conjugates and immunotoxins Oncomatryx Biopharma, S.L. (Derio, ES) ➤ Try a Free Trial
Pembrolizumab ➤ Try a Free Trial Isoindoline derivative, intermediate, preparation method, pharmaceutical composition and use thereof KANGPU BIOPHARMACEUTICALS, LTD. (Shanghai, CN) ➤ Try a Free Trial
Pembrolizumab ➤ Try a Free Trial Methods of treatment with antagonists against PD-1 and PD-L1 in combination with radiation therapy MedImmune Limited (Cambridge, GB) ➤ Try a Free Trial
Pembrolizumab ➤ Try a Free Trial Process for preparing an anti-cancer agent, 1-((4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-6-methoxyquinolin-7-yloxy)meth- yl)cyclopropanamine, its crystalline form and its salts Advenchen Pharmaceuticals, LLC (Moorpark, CA) ➤ Try a Free Trial
Drugname Patent Number Patent Title Patent Assignee Estimated Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

International Patents for Pembrolizumab

Drugname Country Document Number Estimated Expiration Related US Patent
Pembrolizumab European Patent Office 3313818 2035-06-26 ➤ Try a Free Trial
Pembrolizumab World Intellectual Property Organization (WIPO) 2016210262 2035-06-26 ➤ Try a Free Trial
Pembrolizumab Canada 2937600 2034-02-06 ➤ Try a Free Trial
Pembrolizumab China 105980411 2034-02-06 ➤ Try a Free Trial
Pembrolizumab European Patent Office 3102606 2034-02-06 ➤ Try a Free Trial
Drugname Country Document Number Estimated Expiration Related US Patent

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Mallinckrodt
Colorcon
Cantor Fitzgerald
Medtronic
Merck
Cipla
Johnson and Johnson
Chinese Patent Office
Cerilliant

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.